Loading clinical trials...

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy | Clinical Trials | Clareo Health

COMPLETED

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

Drug Refractory Partial Epilepsy, A Therapeutic Trial With Transcranial Magnetic Stimulation

NCT00001666•National Institute of Neurological Disorders and Stroke (NINDS)

View on ClinicalTrials.gov

Summary

Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that can be used to stimulate brain activity and gather information about brain function. It is very useful when studying the areas of the brain related to motor activity (motor cortex, corticospinal tract, and corpus callosum). Epilepsy is a condition associated with seizures as a result of an over excitable cerebral cortex. Despite the introduction of several new antiepileptic medications, less than half of the patients diagnosed with partial epilepsy are well controlled. However, studies have shown that non-invasive stimulation of the brain can decrease the excitability of the cerebral cortex. Researchers are interested in the potential therapeutic effects of TMS on patients with epilepsy that have responded poorly to standard medication. This study will use TMS to decrease the excitability of the areas of the brain responsible for seizures.

Detailed Description

The purpose of this protocol is to study the effects of transcranial magnetic stimulation (TMS) at 1 Hz on the excitability of the seizure focus in patients with poorly controlled epilepsy refractory to pharmacological treatments. 1 Hz TMS is a rate proven to induce long term depression in animal models and reported to decrease the excitability of both human and animal cerebral cortex.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 5 to 60 at entry to protocol.
•History of partial or Complex Partial Epilepsy for two or more years.
•Patients should be on a stable anti-convulsant regimen defined as unchanged medicines and dose modifications lower than 20% in the last month. Blood levels of anti-convulsants will be measured at the beginning of the study, prior to stimulation and after the study to assure that the type and dose of medication will remain constant.
•Seizures not completely responsive to medical treatment (1 or more seizures per week for at least 6 months) and patients have failed at least two anti-convulsant regimens in the past.
•The patients have a localized seizure focus.
•Epilepsy refractory to medical treatments.
•No pregnant women (will be tested with urine pregnancy test).
•No severe coronary disease.
•No metal anywhere in the cranium except the mouth.
•No intracardiac lines.
+4 more criteria

Locations (1)

National Institute of Neurological Disorders and Stroke (NINDS)

Bethesda, Maryland, United States

Key Dates

Start Date

March 1, 1997

Completion Date

June 1, 2002

Last Updated

March 4, 2008

Enrollment

Estimated participants

Conditions

Partial EpilepsySeizures

Interventions

Cadwell High-Speed Magnetoelectric Stimulator

DEVICE

Magpro High-Speed Magnetoelectric Stimulator

DEVICE

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904

Stereotypical Prolonged Seizures

View study

RECRUITINGPHASE3

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142

Primary Generalized Tonic-Clonic Seizures

View study

RECRUITINGPHASE3

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 4, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

Inclusion Criteria

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome

Longitudinal Study of Neurogenetic Disorders

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

Pharmacological Modulation of Brain Oscillations in Memory Processing